Document is current
Any future updates will be listed below
-
Authors
De Leo, Federica
Rossi, Alice
De Marchis, Francesco
Cigana, Cristina
Melessike, Medede
Quilici, Giacomo
De Fino, Ida
Mantonico, Malisa Vittoria
Fabris, Chantal
Bragonzi, Alessandra
Bianchi, Marco Emilio
Musco, Giovanna https://orcid.org/0000-0002-0469-2994
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (21440)
Fondazione per la Ricerca sulla Fibrosi Cistica (FFC#22/2018)
Fondazione Umberto Veronesi
- License Information
-
More Information
Article History
Received: 8 April 2022
Accepted: 25 August 2022
First Online: 7 September 2022
Declarations
:
: Animal studies adhered strictly to the Italian Ministry of Health guidelines for the use and care of experimental animals (protocol #733). Research with the <i>P. aeruginosa</i> multidrug-resistant (MDR)-RP73 isolate from a CF individual and storage of biological materials were approved by the Ethics Commission of Hannover Medical School, Germany.
: Not applicable.
: The authors declare that they have no conflict of interest. However, M.E.B. is founder and part-owner of HMGBiotech, a company that provides goods and services related to HMGB proteins.
